Innovative Therapeutic Approaches for Immune Thrombocytopenia

Join us for a live interactive webinar in conjunction with the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress 2021, to learn more about the latest therapeutic approaches for immune thrombocytopenia (ITP). Featuring presentations, panel discussions with perspectives and recommendations, this webinar will also offer attendees the opportunity to have their questions answered by an international expert panel.

Please note: You must be registered to attend the 2021 International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress to attend this symposium.

To Register: https://www.isth2021.org/register

Agenda

*Date and Time: 19/7/2021, 13:00 - 14:00 CEST

Overview of Emerging Therapies in ITP – David Kuter

FcRn Pathway Inhibition in ITP – Adrian Newland

BTK Inhibition in ITP – David Kuter

Complement Inhibition in ITP – Catherine M. Broome

Summary, Final Thoughts and Q&A

Events

Date / Time
Event Details

Faculty

Program Director
David Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts, USA

Faculty
Catherine M. Broome, MD

Associate Professor of Medicine
Lombardi Cancer Center
MedStar Georgetown University
Washington, DC

Faculty
Adrian Newland, MD

Professor of Haematology
Dept of Haematology
Barts and the London School of Medicine and Dentistry,
London, UK

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate emerging and innovative therapies for ITP.

Target Audience
This program is intended for global physicians and other healthcare professionals who care for patients with ITP.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe recent advances in the understanding of immune thrombocytopenia pathophysiology that have led to the development of new targeted therapies
  • Identify the mechanism of action of novel targeted therapies that are being tested for patients with immune thrombocytopenia
  • Evaluate the available efficacy and safety data for novel targeted therapies in patients with immune thrombocytopenia
  • Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Provided by Clinical Care Options, LLC

Supported by an educational grant from

UCB

There are no fees required to participate in this activity.